The fluorometric microculture cytotoxicity assay von Lindhagen, Elin, Nygren, Peter, Larsson, Rolf

Volltext

Towards streamlined product information: reporting of transporter-mediated drug interactions von Asmar, Valeria, Bergman, Erik, Lindhagen, Elin, Sherwood, Kim, Westman, Gabriel, Gaugaz, Fabienne Zdenka

Volltext

Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartments von Fuchs, Dieter, Christofferson, Rolf, Stridsberg, Mats, Lindhagen, Elin, Azarbayjani, Faranak

Volltext

In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues von Haglund, Caroline, Åleskog, Anna, Nygren, Peter, Gullbo, Joachim, Höglund, Martin, Wickström, Malin, Larsson, Rolf, Lindhagen, Elin

Volltext

The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing von Haglund, Caroline, Åleskog, Anna, Håkansson, Lena Douhan, Höglund, Martin, Jacobsson, Stefan, Larsson, Rolf, Lindhagen, Elin

Volltext

A Phase I Study of CHS 828 in Patients with Solid Tumor Malignancy von HOVSTADIUS, Peter, LARSSON, Rolf, JONSSON, Elin, SKOV, Torsten, KISSMEYER, Anne-Marie, KRASILNIKOFF, Klaus, BERGH, Jonas, KARLSSON, Mats O, LÖNNEBO, Anna, AHLGREN, Johan

Volltext

Screening for Cytotoxic Compounds in Poor-prognostic Chronic Lymphocytic Leukemia von NORBERG, Maria, LINDHAGEN, Elin, KANDURI, Meena, RICKARDSON, Linda, SUNDSTRÖM, Christer, STAMATOPOULOS, Kostas, ROSENQUIST, Richard, ALESKOG, Anna

Volltext

Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia von Lindhagen, Elin, Eriksson, Anna, Wickström, Malin, Danielsson, Katarina, Grundmark, Birgitta, Henriksson, Roger, Nygren, Peter, Åleskog, Anna, Larsson, Rolf, Höglund, Martin

Volltext

Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia von Eriksson, Anna, Höglund, Martin, Lindhagen, Elin, Åleskog, Anna, Hassan, Sadia Bashir, Ekholm, Carina, Fhölenhag, Karin, Jensen, Annika Jenmalm, Löthgren, Agneta, Scobie, Martin, Larsson, Rolf, Parrow, Vendela

Volltext

In vitro activity of bortezomib in cultures of patient tumour cells—potential utility in haematological malignancies von Wiberg, Kristina, Carlson, Kristina, Åleskog, Anna, Larsson, Rolf, Nygren, Peter, Lindhagen, Elin

Volltext

The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia von Eriksson, A, Hermanson, M, Wickström, M, Lindhagen, E, Ekholm, C, Jenmalm Jensen, A, Löthgren, A, Lehmann, F, Larsson, R, Parrow, V, Höglund, M

Volltext

Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination von Åleskog, Anna, Norberg, Maria, Nygren, Peter, Rickardson, Linda, Kanduri, Meena, Tobin, Gerard, Åberg, Magnus, Gustafsson, Mats G., Rosenquist, Richard, Lindhagen, Elin

Volltext

Primary lymphocytes as predictors for species differences in cytotoxic drug sensitivity von Hassan, S.B., Haglund, C., A˚leskog, A., Larsson, R., Lindhagen, E.

Volltext

Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro von Lindhagen, Elin, Rickardson, Linda, Elliott, Gary, Leoni, Lorenzo, Nygren, Peter, Larsson, Rolf, Aleskog, Anna

Volltext

R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leu... von LINDHAGEN, Elin, NISSLE, Sara, LEONI, Lorenzo, ELLIOTT, Gary, QI CHAO, LARSSON, Rolf, ALESKOG, Anna

Volltext

Modeling of In Vitro Drug Activity and Prediction of Clinical Outcome in Acute Myeloid Leukemia von Quartino, Angelica, Karlsson, Mats O., Freijs, Agneta, Jonsson, Niclas, Nygren, Peter, Kristensen, Jörgen, Lindhagen, Elin, Larsson, Rolf

Volltext

CHS 828 Kill Tumour Cells by Inhibiting the Nuclear Factor-κB Translocation but Unlikely through Down-regulation of Proteasome von SAADIA B. HASSAN, HENRIK LÖVBORG, ELIN LINDHAGEN, MATS O. KARLSSON, ROLF LARSSON

Volltext

CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome von Hassan, Saadia B, Lövborg, Henrik, Lindhagen, Elin, Karlsson, Mats O, Larsson, Rolf

Volltext

In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia - rolipram and prednisolone active in cells from patients with poor prognosis von Lindhagen, Elin, Norberg, Maria, Kanduri, Meena, Tobin, Gerard, Säisänen, Laura, Åberg, Magnus, Gustafsson, Mats G., Sundström, Christer, Rosenquist, Richard, Åleskog, Anna

Volltext

CHS 828 kill tumour cells by inhibiting the nuclear factor-κB translocation but unlikely through down-regulation of proteasome von HASSAN, Saadia B, LÖVBORG, Henrik, LINDHAGEN, Elin, KARLSSON, Mats O, LARSSON, Rolf

Volltext